Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Identifieur interne : 002860 ( PubMed/Checkpoint ); précédent : 002859; suivant : 002861Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Auteurs : Nicholas C. Turner [Australie] ; Jungsil Ro ; Fabrice André ; Sherene Loi ; Sunil Verma ; Hiroji Iwata ; Nadia Harbeck ; Sibylle Loibl ; Cynthia Huang Bartlett ; Ke Zhang ; Carla Giorgetti ; Sophia Randolph ; Maria Koehler ; Massimo CristofanilliSource :
- The New England journal of medicine [ 1533-4406 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Femelle, Humains, Inhibiteurs de protéines kinases (effets indésirables), Inhibiteurs de protéines kinases (usage thérapeutique), Kinase-4 cycline-dépendante (antagonistes et inhibiteurs), Kinase-6 cycline-dépendante (antagonistes et inhibiteurs), Marqueurs biologiques (analyse), Méthode en double aveugle, Oestradiol (analogues et dérivés), Oestradiol (effets indésirables), Oestradiol (usage thérapeutique), Pipérazines (effets indésirables), Pipérazines (usage thérapeutique), Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Pyridines (effets indésirables), Pyridines (usage thérapeutique), Récepteur ErbB-2 (analyse), Récepteurs des oestrogènes (analyse), Récepteurs à la progestérone (analyse), Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Tumeurs du sein (traitement médicamenteux).
- MESH :
- analogues et dérivés : Oestradiol.
- analyse : Marqueurs biologiques, Récepteur ErbB-2, Récepteurs des oestrogènes, Récepteurs à la progestérone.
- antagonistes et inhibiteurs : Kinase-4 cycline-dépendante, Kinase-6 cycline-dépendante.
- effets indésirables : Inhibiteurs de protéines kinases, Oestradiol, Pipérazines, Protocoles de polychimiothérapie antinéoplasique, Pyridines.
- traitement médicamenteux : Tumeurs du sein.
- usage thérapeutique : Inhibiteurs de protéines kinases, Oestradiol, Pipérazines, Protocoles de polychimiothérapie antinéoplasique, Pyridines.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Méthode en double aveugle, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Biomarkers (analysis), Breast Neoplasms (drug therapy), Cyclin-Dependent Kinase 4 (antagonists & inhibitors), Cyclin-Dependent Kinase 6 (antagonists & inhibitors), Disease-Free Survival, Double-Blind Method, Estradiol (adverse effects), Estradiol (analogs & derivatives), Estradiol (therapeutic use), Female, Humans, Middle Aged, Piperazines (adverse effects), Piperazines (therapeutic use), Protein Kinase Inhibitors (adverse effects), Protein Kinase Inhibitors (therapeutic use), Pyridines (adverse effects), Pyridines (therapeutic use), Receptor, ErbB-2 (analysis), Receptors, Estrogen (analysis), Receptors, Progesterone (analysis).
- MESH :
- chemical , adverse effects : Estradiol, Piperazines, Protein Kinase Inhibitors, Pyridines.
- chemical , analogs & derivatives : Estradiol.
- chemical , analysis : Biomarkers, Receptor, ErbB-2, Receptors, Estrogen, Receptors, Progesterone.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- chemical , antagonists & inhibitors : Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6.
- drug therapy : Breast Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols, Estradiol, Piperazines, Protein Kinase Inhibitors, Pyridines.
- Adult, Aged, Aged, 80 and over, Disease-Free Survival, Double-Blind Method, Female, Humans, Middle Aged.
Abstract
Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer.
DOI: 10.1056/NEJMoa1505270
PubMed: 26030518
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26030518Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.</title><author><name sortKey="Turner, Nicholas C" sort="Turner, Nicholas C" uniqKey="Turner N" first="Nicholas C" last="Turner">Nicholas C. Turner</name><affiliation wicri:level="4"><nlm:affiliation>From Royal Marsden Hospital, London (N.C.T.); National Cancer Center, Goyang-si, South Korea (J.R.); Institut Gustave Roussy, Villejuif, France (F.A.); Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia (S. Loi); Sunnybrook Odette Cancer Centre, Toronto (S.V.); Aichi Cancer Center Hospital, Nagoya, Japan (H.I.); Brustzentrum der Universität München, Munich (N.H.), and German Breast Group Forschungs, Neu-Isenburg (S. Loibl) - both in Germany; Pfizer, New York (C.H.B., M.K.), La Jolla, CA (K.Z., S.R.), and Milan (C.G.); and Thomas Jefferson University, Philadelphia (M.C.).</nlm:affiliation><orgName type="university">Université de Melbourne</orgName><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Ro, Jungsil" sort="Ro, Jungsil" uniqKey="Ro J" first="Jungsil" last="Ro">Jungsil Ro</name></author><author><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="André">Fabrice André</name></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name></author><author><name sortKey="Verma, Sunil" sort="Verma, Sunil" uniqKey="Verma S" first="Sunil" last="Verma">Sunil Verma</name></author><author><name sortKey="Iwata, Hiroji" sort="Iwata, Hiroji" uniqKey="Iwata H" first="Hiroji" last="Iwata">Hiroji Iwata</name></author><author><name sortKey="Harbeck, Nadia" sort="Harbeck, Nadia" uniqKey="Harbeck N" first="Nadia" last="Harbeck">Nadia Harbeck</name></author><author><name sortKey="Loibl, Sibylle" sort="Loibl, Sibylle" uniqKey="Loibl S" first="Sibylle" last="Loibl">Sibylle Loibl</name></author><author><name sortKey="Huang Bartlett, Cynthia" sort="Huang Bartlett, Cynthia" uniqKey="Huang Bartlett C" first="Cynthia" last="Huang Bartlett">Cynthia Huang Bartlett</name></author><author><name sortKey="Zhang, Ke" sort="Zhang, Ke" uniqKey="Zhang K" first="Ke" last="Zhang">Ke Zhang</name></author><author><name sortKey="Giorgetti, Carla" sort="Giorgetti, Carla" uniqKey="Giorgetti C" first="Carla" last="Giorgetti">Carla Giorgetti</name></author><author><name sortKey="Randolph, Sophia" sort="Randolph, Sophia" uniqKey="Randolph S" first="Sophia" last="Randolph">Sophia Randolph</name></author><author><name sortKey="Koehler, Maria" sort="Koehler, Maria" uniqKey="Koehler M" first="Maria" last="Koehler">Maria Koehler</name></author><author><name sortKey="Cristofanilli, Massimo" sort="Cristofanilli, Massimo" uniqKey="Cristofanilli M" first="Massimo" last="Cristofanilli">Massimo Cristofanilli</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26030518</idno><idno type="pmid">26030518</idno><idno type="doi">10.1056/NEJMoa1505270</idno><idno type="wicri:Area/PubMed/Corpus">002C14</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002C14</idno><idno type="wicri:Area/PubMed/Curation">002B41</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002B41</idno><idno type="wicri:Area/PubMed/Checkpoint">002B41</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002B41</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.</title><author><name sortKey="Turner, Nicholas C" sort="Turner, Nicholas C" uniqKey="Turner N" first="Nicholas C" last="Turner">Nicholas C. Turner</name><affiliation wicri:level="4"><nlm:affiliation>From Royal Marsden Hospital, London (N.C.T.); National Cancer Center, Goyang-si, South Korea (J.R.); Institut Gustave Roussy, Villejuif, France (F.A.); Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia (S. Loi); Sunnybrook Odette Cancer Centre, Toronto (S.V.); Aichi Cancer Center Hospital, Nagoya, Japan (H.I.); Brustzentrum der Universität München, Munich (N.H.), and German Breast Group Forschungs, Neu-Isenburg (S. Loibl) - both in Germany; Pfizer, New York (C.H.B., M.K.), La Jolla, CA (K.Z., S.R.), and Milan (C.G.); and Thomas Jefferson University, Philadelphia (M.C.).</nlm:affiliation><orgName type="university">Université de Melbourne</orgName><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Ro, Jungsil" sort="Ro, Jungsil" uniqKey="Ro J" first="Jungsil" last="Ro">Jungsil Ro</name></author><author><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="André">Fabrice André</name></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name></author><author><name sortKey="Verma, Sunil" sort="Verma, Sunil" uniqKey="Verma S" first="Sunil" last="Verma">Sunil Verma</name></author><author><name sortKey="Iwata, Hiroji" sort="Iwata, Hiroji" uniqKey="Iwata H" first="Hiroji" last="Iwata">Hiroji Iwata</name></author><author><name sortKey="Harbeck, Nadia" sort="Harbeck, Nadia" uniqKey="Harbeck N" first="Nadia" last="Harbeck">Nadia Harbeck</name></author><author><name sortKey="Loibl, Sibylle" sort="Loibl, Sibylle" uniqKey="Loibl S" first="Sibylle" last="Loibl">Sibylle Loibl</name></author><author><name sortKey="Huang Bartlett, Cynthia" sort="Huang Bartlett, Cynthia" uniqKey="Huang Bartlett C" first="Cynthia" last="Huang Bartlett">Cynthia Huang Bartlett</name></author><author><name sortKey="Zhang, Ke" sort="Zhang, Ke" uniqKey="Zhang K" first="Ke" last="Zhang">Ke Zhang</name></author><author><name sortKey="Giorgetti, Carla" sort="Giorgetti, Carla" uniqKey="Giorgetti C" first="Carla" last="Giorgetti">Carla Giorgetti</name></author><author><name sortKey="Randolph, Sophia" sort="Randolph, Sophia" uniqKey="Randolph S" first="Sophia" last="Randolph">Sophia Randolph</name></author><author><name sortKey="Koehler, Maria" sort="Koehler, Maria" uniqKey="Koehler M" first="Maria" last="Koehler">Maria Koehler</name></author><author><name sortKey="Cristofanilli, Massimo" sort="Cristofanilli, Massimo" uniqKey="Cristofanilli M" first="Massimo" last="Cristofanilli">Massimo Cristofanilli</name></author></analytic><series><title level="j">The New England journal of medicine</title><idno type="eISSN">1533-4406</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Biomarkers (analysis)</term><term>Breast Neoplasms (drug therapy)</term><term>Cyclin-Dependent Kinase 4 (antagonists & inhibitors)</term><term>Cyclin-Dependent Kinase 6 (antagonists & inhibitors)</term><term>Disease-Free Survival</term><term>Double-Blind Method</term><term>Estradiol (adverse effects)</term><term>Estradiol (analogs & derivatives)</term><term>Estradiol (therapeutic use)</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Piperazines (adverse effects)</term><term>Piperazines (therapeutic use)</term><term>Protein Kinase Inhibitors (adverse effects)</term><term>Protein Kinase Inhibitors (therapeutic use)</term><term>Pyridines (adverse effects)</term><term>Pyridines (therapeutic use)</term><term>Receptor, ErbB-2 (analysis)</term><term>Receptors, Estrogen (analysis)</term><term>Receptors, Progesterone (analysis)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs de protéines kinases (effets indésirables)</term><term>Inhibiteurs de protéines kinases (usage thérapeutique)</term><term>Kinase-4 cycline-dépendante (antagonistes et inhibiteurs)</term><term>Kinase-6 cycline-dépendante (antagonistes et inhibiteurs)</term><term>Marqueurs biologiques (analyse)</term><term>Méthode en double aveugle</term><term>Oestradiol (analogues et dérivés)</term><term>Oestradiol (effets indésirables)</term><term>Oestradiol (usage thérapeutique)</term><term>Pipérazines (effets indésirables)</term><term>Pipérazines (usage thérapeutique)</term><term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Pyridines (effets indésirables)</term><term>Pyridines (usage thérapeutique)</term><term>Récepteur ErbB-2 (analyse)</term><term>Récepteurs des oestrogènes (analyse)</term><term>Récepteurs à la progestérone (analyse)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Tumeurs du sein (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Estradiol</term><term>Piperazines</term><term>Protein Kinase Inhibitors</term><term>Pyridines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Estradiol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Biomarkers</term><term>Receptor, ErbB-2</term><term>Receptors, Estrogen</term><term>Receptors, Progesterone</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Oestradiol</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Marqueurs biologiques</term><term>Récepteur ErbB-2</term><term>Récepteurs des oestrogènes</term><term>Récepteurs à la progestérone</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Kinase-4 cycline-dépendante</term><term>Kinase-6 cycline-dépendante</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Cyclin-Dependent Kinase 4</term><term>Cyclin-Dependent Kinase 6</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Inhibiteurs de protéines kinases</term><term>Oestradiol</term><term>Pipérazines</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Pyridines</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Estradiol</term><term>Piperazines</term><term>Protein Kinase Inhibitors</term><term>Pyridines</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Inhibiteurs de protéines kinases</term><term>Oestradiol</term><term>Pipérazines</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Pyridines</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Disease-Free Survival</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Middle Aged</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Méthode en double aveugle</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26030518</PMID><DateCreated><Year>2015</Year><Month>07</Month><Day>16</Day></DateCreated><DateCompleted><Year>2015</Year><Month>07</Month><Day>23</Day></DateCompleted><DateRevised><Year>2016</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>373</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Jul</Month><Day>16</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation></Journal><ArticleTitle>Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.</ArticleTitle><Pagination><MedlinePgn>209-19</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1505270</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This phase 3 study involved 521 patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that had relapsed or progressed during prior endocrine therapy. We randomly assigned patients in a 2:1 ratio to receive palbociclib and fulvestrant or placebo and fulvestrant. Premenopausal or perimenopausal women also received goserelin. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival, objective response, rate of clinical benefit, patient-reported outcomes, and safety. A preplanned interim analysis was performed by an independent data and safety monitoring committee after 195 events of disease progression or death had occurred.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median progression-free survival was 9.2 months (95% confidence interval [CI], 7.5 to not estimable) with palbociclib-fulvestrant and 3.8 months (95% CI, 3.5 to 5.5) with placebo-fulvestrant (hazard ratio for disease progression or death, 0.42; 95% CI, 0.32 to 0.56; P<0.001). The most common grade 3 or 4 adverse events in the palbociclib-fulvestrant group were neutropenia (62.0%, vs. 0.6% in the placebo-fulvestrant group), leukopenia (25.2% vs. 0.6%), anemia (2.6% vs. 1.7%), thrombocytopenia (2.3% vs. 0%), and fatigue (2.0% vs. 1.2%). Febrile neutropenia was reported in 0.6% of palbociclib-treated patients and 0.6% of placebo-treated patients. The rate of discontinuation due to adverse events was 2.6% with palbociclib and 1.7% with placebo.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Among patients with hormone-receptor-positive metastatic breast cancer who had progression of disease during prior endocrine therapy, palbociclib combined with fulvestrant resulted in longer progression-free survival than fulvestrant alone. (Funded by Pfizer; PALOMA3 ClinicalTrials.gov number, NCT01942135.).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Nicholas C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>From Royal Marsden Hospital, London (N.C.T.); National Cancer Center, Goyang-si, South Korea (J.R.); Institut Gustave Roussy, Villejuif, France (F.A.); Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia (S. Loi); Sunnybrook Odette Cancer Centre, Toronto (S.V.); Aichi Cancer Center Hospital, Nagoya, Japan (H.I.); Brustzentrum der Universität München, Munich (N.H.), and German Breast Group Forschungs, Neu-Isenburg (S. Loibl) - both in Germany; Pfizer, New York (C.H.B., M.K.), La Jolla, CA (K.Z., S.R.), and Milan (C.G.); and Thomas Jefferson University, Philadelphia (M.C.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ro</LastName><ForeName>Jungsil</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>André</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Loi</LastName><ForeName>Sherene</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Sunil</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Iwata</LastName><ForeName>Hiroji</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Harbeck</LastName><ForeName>Nadia</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Loibl</LastName><ForeName>Sibylle</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Huang Bartlett</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ke</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Giorgetti</LastName><ForeName>Carla</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Randolph</LastName><ForeName>Sophia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Koehler</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cristofanilli</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><CollectiveName>PALOMA3 Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01942135</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>22X328QOC4</RegistryNumber><NameOfSubstance UI="C070081">fulvestrant</NameOfSubstance></Chemical><Chemical><RegistryNumber>4TI98Z838E</RegistryNumber><NameOfSubstance UI="D004958">Estradiol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="C495900">CDK4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="C495911">CDK6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="D051358">Cyclin-Dependent Kinase 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="D051361">Cyclin-Dependent Kinase 6</NameOfSubstance></Chemical><Chemical><RegistryNumber>G9ZF61LE7G</RegistryNumber><NameOfSubstance UI="C500026">palbociclib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Clin Oncol. 2015 Aug;12(8):436</RefSource><PMID Version="1">26122184</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2015 Oct 22;373(17):1672-3</RefSource><PMID Version="1">26488700</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2015 Oct 22;373(17):1672-3</RefSource><PMID Version="1">26488701</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2015 Jul 16;373(3):273-4</RefSource><PMID Version="1">26176385</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051358" MajorTopicYN="N">Cyclin-Dependent Kinase 4</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051361" MajorTopicYN="N">Cyclin-Dependent Kinase 6</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>André</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cristofanilli</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glück</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harbeck</LastName><ForeName>Nadia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iwata</LastName><ForeName>Hiroji</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loi</LastName><ForeName>Sherene</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loibl</LastName><ForeName>Sybille</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verma</LastName><ForeName>Sunil</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vermorken</LastName><ForeName>Jan B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seidman</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Emerson</LastName><ForeName>Scott S</ForeName><Initials>SS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antill</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ganju</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oakman</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Redfern</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Slancar</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khasraw</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cronk</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lombard</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dirix</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canon</LastName><ForeName>J -L</ForeName><Initials>J-</Initials></Investigator><Investigator ValidYN="Y"><LastName>Confente</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wynendaele</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neven</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vuylsteke</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baurain</LastName><ForeName>J -F</ForeName><Initials>J-</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duck</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forget</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Awada</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dopchie</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verma</LastName><ForeName>Sunil</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verma</LastName><ForeName>Shailendra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elser</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Findlay</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>L A</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ellard</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freedman</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loibl</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forstmeyer</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harbeck</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murphy</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soto Parra</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zamagni</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colleoni</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barone</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Laurentis</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gianni</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roila</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amadori</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Inoue</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iwata</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mukai</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masuda</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rai</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hara</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ishida</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakamura</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>S -B</ForeName><Initials>S-</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ro</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Im</LastName><ForeName>S -A</ForeName><Initials>S-</Initials></Investigator><Investigator ValidYN="Y"><LastName>Im</LastName><ForeName>Y -H</ForeName><Initials>Y-</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kroep</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Portielje</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Jongh</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Alphen</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erdkamp</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Boer</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cardoso</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bordalo e Sa</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toganel</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ganea</LastName><ForeName>D E</ForeName><Initials>DE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crihana</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turcu</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vladimirov</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipatov</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Komov</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fadeeva</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krasnozhon</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chang</LastName><ForeName>T -W</ForeName><Initials>T-</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gokmen</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shevnia</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berzoy</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shparyk</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hontsa</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vinnyk</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Archer</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coleman</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barrett-Lee</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henderson</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalmadi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilkinson</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldberg</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tiber</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beeker</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kabos</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Rourke</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Link</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Citron</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Margileth</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeMichele</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Helsten</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stearns</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaklavas</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sleckman</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dillon</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hetzel</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Niu</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dichmann</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lawler</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>DiCarlo</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Calfa</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allison</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waisman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krill-Jackson</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mahtani</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burness</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caballero Monge</LastName><ForeName>A Garcia</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huggines-Puhalla</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Slamon</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beck</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toppmeyer</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rao</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jaslow</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weisberg</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chalasani</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rakkar</LastName><ForeName>A N</ForeName><Initials>AN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lashkari</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adoo</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>McIntyre</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Houck</LastName><ForeName>W</ForeName><Initials>W</Initials><Suffix>3rd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Vukelja</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilks</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Restrepo</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rugo</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Danso</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robert</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hermann</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lindquist</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ellis</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moroose</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26030518</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1505270</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li></country><region><li>Victoria (État)</li></region><settlement><li>Melbourne</li></settlement><orgName><li>Université de Melbourne</li></orgName></list><tree><noCountry><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="André">Fabrice André</name><name sortKey="Cristofanilli, Massimo" sort="Cristofanilli, Massimo" uniqKey="Cristofanilli M" first="Massimo" last="Cristofanilli">Massimo Cristofanilli</name><name sortKey="Giorgetti, Carla" sort="Giorgetti, Carla" uniqKey="Giorgetti C" first="Carla" last="Giorgetti">Carla Giorgetti</name><name sortKey="Harbeck, Nadia" sort="Harbeck, Nadia" uniqKey="Harbeck N" first="Nadia" last="Harbeck">Nadia Harbeck</name><name sortKey="Huang Bartlett, Cynthia" sort="Huang Bartlett, Cynthia" uniqKey="Huang Bartlett C" first="Cynthia" last="Huang Bartlett">Cynthia Huang Bartlett</name><name sortKey="Iwata, Hiroji" sort="Iwata, Hiroji" uniqKey="Iwata H" first="Hiroji" last="Iwata">Hiroji Iwata</name><name sortKey="Koehler, Maria" sort="Koehler, Maria" uniqKey="Koehler M" first="Maria" last="Koehler">Maria Koehler</name><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><name sortKey="Loibl, Sibylle" sort="Loibl, Sibylle" uniqKey="Loibl S" first="Sibylle" last="Loibl">Sibylle Loibl</name><name sortKey="Randolph, Sophia" sort="Randolph, Sophia" uniqKey="Randolph S" first="Sophia" last="Randolph">Sophia Randolph</name><name sortKey="Ro, Jungsil" sort="Ro, Jungsil" uniqKey="Ro J" first="Jungsil" last="Ro">Jungsil Ro</name><name sortKey="Verma, Sunil" sort="Verma, Sunil" uniqKey="Verma S" first="Sunil" last="Verma">Sunil Verma</name><name sortKey="Zhang, Ke" sort="Zhang, Ke" uniqKey="Zhang K" first="Ke" last="Zhang">Ke Zhang</name></noCountry><country name="Australie"><region name="Victoria (État)"><name sortKey="Turner, Nicholas C" sort="Turner, Nicholas C" uniqKey="Turner N" first="Nicholas C" last="Turner">Nicholas C. Turner</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002860 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002860 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:26030518
|texte= Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26030518" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |